Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Neurocrine Biosciences (NBIX) stock
Learn how to easily invest in Neurocrine Biosciences stock.
Neurocrine Biosciences, Inc is a biotechnology business based in the US. Neurocrine Biosciences shares (NBIX) are listed on the NASDAQ and all prices are listed in US Dollars. Neurocrine Biosciences employs 865 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Neurocrine Biosciences
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – NBIX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Neurocrine Biosciences stock price (NASDAQ: NBIX)Use our graph to track the performance of NBIX stocks over time.
Neurocrine Biosciences shares at a glance
|Latest market close||$96.22|
|52-week range||$86.02 - $127.18|
|50-day moving average||$97.78|
|200-day moving average||$99.92|
|Wall St. target price||$122.90|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$4.09|
Buy Neurocrine Biosciences shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Neurocrine Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Neurocrine Biosciences price performance over time
|1 week (2021-07-14)||N/A|
|1 month (2021-06-25)||-4.06%|
|3 months (2021-04-21)||N/A|
|6 months (2021-01-21)||N/A|
|1 year (2020-07-21)||N/A|
|2 years (2019-07-21)||N/A|
|3 years (2018-07-21)||N/A|
|5 years (2016-07-21)||N/A|
Is Neurocrine Biosciences under- or over-valued?
Valuing Neurocrine Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neurocrine Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Neurocrine Biosciences's P/E ratio
Neurocrine Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Neurocrine Biosciences shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Neurocrine Biosciences's PEG ratio
Neurocrine Biosciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.87. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Neurocrine Biosciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Neurocrine Biosciences's EBITDA
Neurocrine Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $309.1 million.
The EBITDA is a measure of a Neurocrine Biosciences's overall financial performance and is widely used to measure a its profitability.
Neurocrine Biosciences financials
|Revenue TTM||$1 billion|
|Operating margin TTM||28.71%|
|Gross profit TTM||$760.8 million|
|Return on assets TTM||11.69%|
|Return on equity TTM||42.19%|
|Market capitalisation||$9.3 billion|
TTM: trailing 12 months
Shorting Neurocrine Biosciences shares
There are currently 4.4 million Neurocrine Biosciences shares held short by investors – that's known as Neurocrine Biosciences's "short interest". This figure is 1.2% down from 4.4 million last month.
There are a few different ways that this level of interest in shorting Neurocrine Biosciences shares can be evaluated.
Neurocrine Biosciences's "short interest ratio" (SIR)
Neurocrine Biosciences's "short interest ratio" (SIR) is the quantity of Neurocrine Biosciences shares currently shorted divided by the average quantity of Neurocrine Biosciences shares traded daily (recently around 777887.74422735). Neurocrine Biosciences's SIR currently stands at 5.63. In other words for every 100,000 Neurocrine Biosciences shares traded daily on the market, roughly 5630 shares are currently held short.
However Neurocrine Biosciences's short interest can also be evaluated against the total number of Neurocrine Biosciences shares, or, against the total number of tradable Neurocrine Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neurocrine Biosciences's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Neurocrine Biosciences shares in existence, roughly 50 shares are currently held short) or 0.047% of the tradable shares (for every 100,000 tradable Neurocrine Biosciences shares, roughly 47 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Neurocrine Biosciences.
Find out more about how you can short Neurocrine Biosciences stock.
Neurocrine Biosciences share dividends
We're not expecting Neurocrine Biosciences to pay a dividend over the next 12 months.
Neurocrine Biosciences share price volatility
Over the last 12 months, Neurocrine Biosciences's shares have ranged in value from as little as $86.02 up to $127.175. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurocrine Biosciences's is 0.7557. This would suggest that Neurocrine Biosciences's shares are less volatile than average (for this exchange).
Neurocrine Biosciences overview
Neurocrine Biosciences, Inc. , a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1. 6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.
Stocks similar to Neurocrine Biosciences
Neurocrine Biosciences in the news
Hedge Funds Never Been Less Bullish On Neurocrine Biosciences, Inc. (NBIX)
New York State Teachers Retirement System Buys Travel+Leisure Co, Aspen Technology Inc, Lattice Semiconductor Corp, Sells Seagate Technology Holdings PLC, , Travel+Leisure Co
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results
Frequently asked questionsWhat percentage of Neurocrine Biosciences is owned by insiders or institutions?
Currently 1.344% of Neurocrine Biosciences shares are held by insiders and 103.636% by institutions. How many people work for Neurocrine Biosciences?
Latest data suggests 865 work at Neurocrine Biosciences. When does the fiscal year end for Neurocrine Biosciences?
Neurocrine Biosciences's fiscal year ends in December. Where is Neurocrine Biosciences based?
Neurocrine Biosciences's address is: 12780 El Camino Real, San Diego, CA, United States, 92130 What is Neurocrine Biosciences's ISIN number?
Neurocrine Biosciences's international securities identification number is: US64125C1099 What is Neurocrine Biosciences's CUSIP number?
Neurocrine Biosciences's Committee on Uniform Securities Identification Procedures number is: 64125C109
More guides on Finder
How to buy Clover Finance (CLV) in the US
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
How to buy AT-and-T (T) stock
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
How to buy Hellenic Coin (HNC) in the US
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
How to buy Maro (MARO) in the US
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
How to buy Ethernity Chain (ERN) in the US
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
How to buy Shopping.io (SPI) in the US
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
How to buy LUKSO Token (LYXE) in the US
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
How to buy KardiaChain (KAI) in the US
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
How to buy Neutrino USD (USDN) in the US
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
How to buy Venus BTC (VBTC) in the US
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
Ask an Expert